bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its lentiviral vector (LVV) gene addition platform. It markets three gene therapies: ZYNTEGLO (betibeglogene autotemcel, also known as beti-cel), SKYSONA (elivaldogene autotemcel, also known as eli-cel), and LYFGENIA (lovotibeglogene autotemcel, also known as lovo-cel). ZYNTEGLO is the first gene therapy for the treatment of adult and pediatric patients with ß-thalassemia who require regular red blood cell transfusions. SKYSONA is used to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). LYFGENIA was approved by the FDA for the treatment of patients 12 years of age or older with sickle cell disease (SCD) and a history of vaso-occlusive events (VOEs). It is focused on pursuing curative gene therapies.

• Revenue in USD (TTM)54.90m
• Net income in USD-311.44m
• Incorporated1992
• Employees375.00

• Location
  bluebird bio Inc455 Grand Union BoulevardSOMERVILLE 02145United StatesUSA
• Phone+1 (339) 499-9300
• Fax+1 (302) 636-5454
• Websitehttps://www.bluebirdbio.com/